Please assess the completion status of the following clinical trial:

Trial Title: Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary bloodstream infections by any specie of the Enterobacterales family with minimum inhibitory concentration (MIC) for meropenem \>32mg/L;~* Agreement of the assistant team with the inclusion of the patient in the study;~* Agreement by the patient or legal guardian to sign the informed consent form.~Exclusion Criteria:~* Known pregnancy;~* Patients belonging to the population deprived of their liberty;~* Known allergy to meropenem;~* Use of ceftazidime-avibactam (or any other new antimicrobial agent that become available in Brazil during the study period) for the treatment of the current infection;~* Infection by an Enterobacterales isolates without in vitro susceptibility to at least one antimicrobial drug;~* Bloodstream co-infection by another gram negative bacilli;~* Concomitant infection at any site by a pathogen which meropenem is indicated;~* Neutropenia (\<1000 neutrophils cells/mm3)~* Death expected within 48 hours of eligibility assessment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meropenem plus Best Available Therapy plus (Type: EXPERIMENTAL): Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~1. Polymyxin B or colistimethate;~2. Amikacin or gentamicin;~3. Tigecycline;~4. Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team.
- Best Available Therapy (Type: NO_INTERVENTION): The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~1. Polymyxin B or colistimethate;~2. Amikacin or gentamicin;~3. Tigecycline;~4. Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team.

Based on this trial design, predict the completion outcome and termination type (if applicable).